Free Trial

ADC Therapeutics (ADCT) Competitors

ADC Therapeutics logo
$2.68 -0.01 (-0.19%)
Closing price 03:59 PM Eastern
Extended Trading
$2.70 +0.03 (+1.12%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADCT vs. PAHC, PHVS, ARDX, GPCR, AMPH, VERV, SYRE, AKBA, RCUS, and COLL

Should you be buying ADC Therapeutics stock or one of its competitors? The main competitors of ADC Therapeutics include Phibro Animal Health (PAHC), Pharvaris (PHVS), Ardelyx (ARDX), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Verve Therapeutics (VERV), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), Arcus Biosciences (RCUS), and Collegium Pharmaceutical (COLL). These companies are all part of the "pharmaceutical products" industry.

ADC Therapeutics vs. Its Competitors

Phibro Animal Health (NASDAQ:PAHC) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

In the previous week, Phibro Animal Health had 9 more articles in the media than ADC Therapeutics. MarketBeat recorded 10 mentions for Phibro Animal Health and 1 mentions for ADC Therapeutics. Phibro Animal Health's average media sentiment score of 1.03 beat ADC Therapeutics' score of -0.50 indicating that Phibro Animal Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Phibro Animal Health
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
ADC Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by insiders. Comparatively, 5.4% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Phibro Animal Health has a net margin of 2.68% compared to ADC Therapeutics' net margin of -197.64%. Phibro Animal Health's return on equity of 30.51% beat ADC Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Phibro Animal Health2.68% 30.51% 6.89%
ADC Therapeutics -197.64%N/A -45.57%

Phibro Animal Health presently has a consensus price target of $24.40, indicating a potential downside of 14.51%. ADC Therapeutics has a consensus price target of $7.75, indicating a potential upside of 189.72%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Phibro Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Phibro Animal Health
2 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.83
ADC Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Phibro Animal Health has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500.

Phibro Animal Health has higher revenue and earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phibro Animal Health$1.02B1.14$2.42M$0.7836.59
ADC Therapeutics$70.84M3.75-$157.85M-$1.45-1.84

Summary

Phibro Animal Health beats ADC Therapeutics on 10 of the 15 factors compared between the two stocks.

Get ADC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ADCT vs. The Competition

MetricADC TherapeuticsMED IndustryMedical SectorNYSE Exchange
Market Cap$265.80M$2.98B$5.45B$20.61B
Dividend YieldN/A2.28%4.60%3.65%
P/E RatioN/A17.1629.7827.95
Price / Sales3.75171.23376.6288.33
Price / CashN/A40.7324.8417.60
Price / Book-1.278.898.604.60
Net Income-$157.85M-$54.75M$3.26B$994.60M
7 Day Performance-1.83%-2.08%0.55%0.27%
1 Month Performance-15.35%1.89%1.41%-1.22%
1 Year Performance0.56%8.52%36.52%14.31%

ADC Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ADCT
ADC Therapeutics
1.5632 of 5 stars
$2.68
-0.2%
$7.75
+189.7%
+1.5%$265.80M$70.84M0.00310Upcoming Earnings
PAHC
Phibro Animal Health
4.1377 of 5 stars
$27.14
+3.9%
$24.40
-10.1%
+59.6%$1.06B$1.02B34.801,940News Coverage
Positive News
Analyst Revision
PHVS
Pharvaris
1.6499 of 5 stars
$21.24
+6.2%
$36.20
+70.4%
+25.1%$1.05BN/A-7.0630Upcoming Earnings
ARDX
Ardelyx
4.3366 of 5 stars
$4.39
+1.4%
$10.88
+147.7%
-8.6%$1.04B$333.61M-19.9590Earnings Report
Analyst Upgrade
GPCR
Structure Therapeutics
1.8152 of 5 stars
$16.78
-4.6%
$76.17
+353.9%
-51.7%$1.01BN/A-19.29136Trending News
Earnings Report
Analyst Revision
AMPH
Amphastar Pharmaceuticals
3.2697 of 5 stars
$21.40
+0.9%
$32.33
+51.1%
-44.4%$999.82M$731.97M7.752,028Analyst Forecast
Gap Up
VERV
Verve Therapeutics
2.8913 of 5 stars
$11.13
flat
$14.57
+30.9%
N/A$992.13M$32.33M-5.27110Upcoming Earnings
SYRE
Spyre Therapeutics
2.4079 of 5 stars
$16.16
-0.6%
$53.40
+230.4%
-38.9%$980.08M$890K-4.2973Positive News
Earnings Report
AKBA
Akebia Therapeutics
3.9453 of 5 stars
$3.76
+1.1%
$6.75
+79.5%
+208.1%$977.01M$160.18M-17.90430
RCUS
Arcus Biosciences
2.3298 of 5 stars
$9.22
+0.6%
$21.29
+131.0%
-41.8%$969.91M$258M-2.20500Trending News
Earnings Report
Analyst Upgrade
Analyst Revision
COLL
Collegium Pharmaceutical
2.9249 of 5 stars
$31.09
+3.4%
$43.75
+40.7%
-1.6%$966.20M$631.45M25.48210Analyst Upgrade

Related Companies and Tools


This page (NYSE:ADCT) was last updated on 8/11/2025 by MarketBeat.com Staff
From Our Partners